ATLASLigand Pharmaceuticals (LGND) earnings date: expected January 18–24
Ligand Pharmaceuticals (LGND) has not announced its next earnings date yet. Based on its last 4 reports, ATLAS expects it around January 18–24. That is an estimate, not a confirmed date.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on LGND
| Last price | $322.75 (+1.7%) |
|---|---|
| Normal 1-day range (±1σ) | ±2.0% |
| Earnings beat history | Beat the EPS estimate in 4 of the last 6 reports |
These figures come from the same calibrated model and valuation as the Ligand Pharmaceuticals stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Expected around January 18–24 (estimate). One email the day before, with ATLAS’s read on Ligand Pharmaceuticals. You can switch it off at any time.
Alert me before LGND reportsFree to start. Creating an account takes under a minute.
LGND earnings at a glance
| Next report | Not announced · expected around January 18–24 (ATLAS estimate) |
|---|---|
| Last report | Oct 29, 2026 · Miss |
| Beat rate (last 6 reports) | 4 of 6 (67%) |
| Average EPS surprise | +2.9% |
| Average move around a report | ±3.6% (last 5) |
| Sector | Healthcare · Biotechnology |
The expected window is an ATLAS estimate: it takes the typical gap between Ligand Pharmaceuticals’s last 4 reports and adds it to the most recent one. Companies announce the real date a few weeks ahead, and ATLAS switches the page to the confirmed date as soon as it is published.
Ligand Pharmaceuticals earnings history: last 6 reports
Ligand Pharmaceuticals last reported on Oct 29, 2026: EPS of -$1.43 against an estimate of $1.42 (-200.7% surprise), a miss.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Oct 29, 2026 | $1.42 | -$1.43 | -200.7% | Miss | – |
| Aug 6, 2026 | $1.95 | $2.37 | +21.5% | Beat | -3.1% |
| May 7, 2026 | $1.80 | $1.63 | -9.4% | Miss | -4.8% |
| Feb 26, 2026 | $1.50 | $2.02 | +34.7% | Beat | +3.6% |
| Dec 9, 2025 | $0.18 | $0.38 | +111.1% | Beat | -0.4% |
| Nov 6, 2025 | $1.93 | $3.09 | +60.1% | Beat | +6.4% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for LGND
See the fair value, the probability range and the earnings history of Ligand Pharmaceuticals on its ATLAS page.
Ligand Pharmaceuticals (LGND) stock analysisPlans from €3.99 a month.
Ligand Pharmaceuticals earnings: frequently asked questions
When is Ligand Pharmaceuticals (LGND) next earnings date?
Ligand Pharmaceuticals has not announced its next report. Its last 4 reports came Oct 29, 2026, Aug 6, 2026, May 7, 2026, Feb 26, 2026, so ATLAS estimates the next one around January 18–24. This is an estimate based on that pattern, not a confirmed date.
How often does LGND beat earnings estimates?
Of its last 6 reports with a recorded result, Ligand Pharmaceuticals beat the EPS estimate 4 times; the average surprise was +2.9%. Past results do not predict the next one.
How much does LGND move around earnings?
Over its last 5 reports the stock moved an average of 3.6% (absolute, from the close before the report day to the close after it), and finished higher 2 of 5 times.
Did Ligand Pharmaceuticals beat earnings estimates last quarter?
Ligand Pharmaceuticals last reported on Oct 29, 2026: EPS of -$1.43 against an estimate of $1.42 (-200.7% surprise), a miss.
How much does LGND usually move in a day?
On a normal trading day the ATLAS model puts LGND’s one-day range at about ±2.0%, with a 50% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Educational information, not investment advice. Disclaimer